Market Research Report

Japan Pacemakers Market Report Key Takeaways:

• The Japan Pacemakers Market size was valued at around USD 118 million in 2025 and is projected to reach USD 153 million by 2032. The estimated CAGR from 2026 to 2032 is around 3.78%, indicating strong growth.
• By product type, the implantable pacemakers seized around 80% of the Japan Pacemakers Market size in 2025.
• By end user, the hospitals & cardiac centers represented 75% of the Japan Pacemakers Market size in 2025.
• By technology, the dual-chamber pacemakers represented 45% of the Japan Pacemakers Market size in 2025.
• The leading pacemaker companies in Japan are Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, Osypka Medical GmbH, BIOTRONIK SE & Co. KG, MicroPort Scientific Corporation, Japan Lifeline Co., Ltd., ZOLL Medical Corporation, and others.

Market Insights & Analysis: Japan Pacemakers Market (2026- 2032):

The Japan Pacemakers Market size was valued at around USD 118 million in 2025 and is projected to reach USD 153 million by 2032. Along with this, the market is estimated to grow at a CAGR of around 3.78% during the forecast period, i.e., 2026-32.

The Japan Pacemakers Market is experiencing rapid growth, driven by the rising burden of cardiovascular diseases and the growing clinical adoption of leadless pacemaker technologies that enhance patient safety, procedural efficiency, and long-term outcomes.

According to the Ministry of Health, Labour and Welfare (MHLW), heart disease (excluding hypertensive disorders) ranked as Japan’s second leading cause of death in 2024, accounting for 14.1% of total mortality .

Overall deaths rose to approximately 1.61 million in 2024 from 1.58 million in the prior year, underscoring the intensifying clinical exposure to serious cardiac conditions. This epidemiological backdrop directly strengthens demand for rhythm management therapies, including permanent pacemaker implantation.

Clinical registries further validate the depth and geographic spread of advanced cardiovascular disease. Japan’s nationwide JROADHF registry enrolled 4,329 hospitalized patients with heart failure with reduced ejection fraction (HFrEF), a population closely associated with bradyarrhythmias and conduction disorders .

Patients were distributed across all major regions, with Kanto (22.1%), Kinki (20.8%), and Chubu (18.0%) representing major concentrations. Ischemic heart disease accounted for 36.3% of cases nationwide, while arrhythmia-related etiologies formed a substantial share, reaching 16.9% in Kinki. These regionally differentiated patterns indicate persistent, localized demand for device-based rhythm management, reinforcing pacemakers as an essential component of Japan’s cardiac care infrastructure.

Technological transformation is amplifying this demand. The Pharmaceuticals and Medical Devices Agency (PMDA) confirmed in September 2024 that Abbott Medical Japan’s Aveir LP leadless pacemaker received expanded review for atrial pacing and AV synchrony, beyond ventricular-only use .

Clinical data demonstrated a 91% composite pacing success at three months and AV synchrony rates of approximately 95.7% among Japanese patients. By eliminating transvenous leads and subcutaneous generator pockets, leadless systems significantly reduce infection risk and procedural complexity, making them increasingly suitable for Japan’s aging and frail patient base.

Furthermore, this shift is reinforcing the dominance of advanced configurations, with dual-chamber pacemakers leading by technology at 45% share, reflecting rising clinical preference for physiologic pacing and AV coordination .

Japan’s cardiovascular disease burden is set to intensify well beyond 2025, underpinned by one of the world’s fastest-aging population profiles. Projections from the National Institute of Population and Social Security Research indicate that by 2070, nearly 40% of Japan’s population will be aged 65 and above, rising from about 29% in 2023, meaning roughly two in every five residents will be elderly. This demographic shift will substantially expand the pool of individuals vulnerable to age-related cardiac conditions, particularly heart failure and arrhythmias, which are primary indications for pacing therapy.

Moreover, the population aged 80 and above is expected to double to approximately 12 million by 2050. Advanced age is a dominant risk factor for atrial fibrillation, conduction disorders, and progressive heart failure, ensuring a structurally rising incidence of rhythm abnormalities.

The convergence of rising cardiovascular mortality, regionally entrenched heart failure prevalence, and rapid adoption of leadless and dual-chamber technologies establishes a durable growth trajectory for Japan’s pacemakers market. As demographic aging accelerates, pacemakers will become increasingly central to national cardiac care delivery, sustaining long-term market expansion.

Japan Pacemakers Market Scope:

Japan Pacemakers Market Drivers:

Rising Incidence of Cardiovascular Diseases

Japan is witnessing a sustained rise in cardiovascular disease (CVD) burden, directly strengthening demand for pacemakers and rhythm-management solutions. The Ministry of Health, Labour and Welfare’s latest Patient Survey shows that 3.58 million people were receiving continuous treatment for heart diseases in 2023, excluding hypertensive heart disease .

This represents an increase of 530,000 patients, that are equivalent to nearly 17% growth in just three years. Within this population, arrhythmia and conduction disorders affected 1.09 million people, while heart failure impacted 722,000 patients and angina pectoris 978,000, highlighting a large and expanding pool of patients clinically aligned with pacemaker therapy .

The disease burden is further amplified by comorbid conditions. Epidemiological research indicates that 63.1% of adults with type-2 diabetes in Japan already have established cardiovascular disease, including coronary and cerebrovascular conditions. This intersection of metabolic and cardiac disorders accelerates progression toward rhythm abnormalities and structural heart disease, reinforcing long-term device demand.

Demographics compound this trend. Japan’s population is aging rapidly, with individuals aged over 75 expected to exceed 20% of the population by 2025 . Advanced age is a primary risk factor for bradyarrhythmias and heart failure, both of which frequently require pacing therapy.

The sharp rise in heart disease prevalence, the million-plus arrhythmia population, and Japan’s accelerating aging curve are structurally expanding the pacemaker candidate base. Together, these forces will continue to propel sustained market growth well beyond 2025.